Volume : VII, Issue : III, March - 2017

ROLE OF FERRIC CARBOXYMALTOSE FOR ANEMIA IN PREGNANCY.

Geeta Rani, Dr Anupama Sinha

Abstract :

 AIMS AND OBJECTIVES –The aim of the study was to assess the safety and efficacy of intravenous Ferric carboxymaltose in pregnant women for correction of mild, moderate and severe anaemia in the second and third trimester. Current options for treatment are limited, these include oral iron supplementation, which can be ineffective and poorly tolerated and red blood cells transfusion, which carry an inherent risk and should be avoided. Ferric carboxymaltose is a new treatment option that may be better tolerated. METHODS:   It was a prospective observational study; 50 anaemic pregnant women received Ferric Carboxymaltose (FCM) upto 15mg /kg between 24 – 40 weeks of pregnancy (median 35 weeks G. age). Efficacy of treatment was assessed by rise in Hb% level after 3 & 6 weeks post infusion. RESULTS: – Intravenous ferric Carboxymaltose infusion, significantly increased the Hb% above baseline levels in all women. Increased Hb values were observed after 3 weeks – 6 weeks.Ferritin values increased significantly after the infusion. Foetal heart rate monitoring did not indicate a drug related negative impact on the foetus.  > 80% of women reported an improvement in their well being. No serious side effects were found and minor side effect was seen in 5 patients. CONCLUSIONS: Ferric Carboxymaltose is a safe and effective treatment of iron deficiency anaemia in pregnancy.

Keywords :

Article: Download PDF   DOI : 10.36106/ijar  

Cite This Article:

Geeta Rani, Dr Anupama Sinha, ROLE OF FERRIC CARBOXYMALTOSE FOR ANEMIA IN PREGNANCY., INDIAN JOURNAL OF APPLIED RESEARCH : Volume‾7 | Issue‾3 | March‾2017

Number of Downloads : 953

References :